2. Search Result
Search Result
Results for "

Hydroxamate

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

3

Peptides

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131894
    DL-Serine hydroxamate

    		Amino Acid Derivatives Others
    DL-Serine hydroxamate is a serine derivative .
    DL-Serine hydroxamate
  • HY-134450
    L-Aspartic acid β-hydroxamate

    		Amino Acid Derivatives Others
    L-Aspartic acid β-hydroxamate is an aspartic acid derivative .
    L-Aspartic acid β-hydroxamate
  • HY-W001857
    Octanohydroxamic acid

    N-Hydroxyoctanamide; Caprylhydroxamic acid

    		 Biochemical Assay Reagents Bacterial Others
    Octanohydroxamic acid (N-Hydroxyoctanamide; Caprylhydroxamic acid) can be used as an extractant for alkaloids, which are used in pharmaceutical and natural product research. Octanohydroxamic acid may also be involved in the inhibition of certain enzymes, such as hydroxamate hydrolases.
    Octanohydroxamic acid
  • HY-CE01798
    Glutamine-hydroxamate-CoA

    Glutamine Hydroxamate-coenzyme A

    		 Biochemical Assay Reagents Metabolic Disease
    Glutamine-hydroxamate-CoA (Glutamine hydroxamate-coenzyme A) is a coenzyme A derivative .
    Glutamine-hydroxamate-CoA
  • HY-135599
    Lysine hydroxamate

    		Bacterial Infection
    Lysine hydroxamate is an amino acid hydroxamate that inhibits the growth of Escherichia coli K-12. Of the other amino acid hydroxamates tested, only L-lysine hydroxamate reduced the growth rate. The inhibition of growth by L-serine hydroxamate could be rapidly reversed by adding L-serine to the bacterial culture or by removing the analog by filtration. This reversal was specific for L-serine. L-alanine, glycine, or adenine had no effect on the inhibited culture. There was no evidence for active transport of the analog.
    Lysine hydroxamate
  • HY-133160
    Valproic acid hydroxamate

    VPA-HA

    		 Drug Derivative Neurological Disease
    Valproic acid hydroxamate (VPA-HA) has shown anticonvulsant activity in a mouse neural tube defect model, without any teratogenic effects .
    Valproic acid hydroxamate
  • HY-118661
    BDM14471

    		Aminopeptidase Others
    BDM14471 is a selective inhibitor of hydroxamate aminopeptidase M1 (PfAM1), with the IC50 of 6 nM .
    BDM14471
  • HY-129580
    Nannochelin B

    		Bacterial Fungal Infection
    Nannochelin B is a novel citrate-hydroxamate siderophore with a growth-inhibitory activity against some bacteria and fungi .
    Nannochelin B
  • HY-159586
    Tyrosinase-IN-32

    		Tyrosinase Cancer
    Tyrosinase-IN-32 (compound 11) is a hydroxamate-based alkaloid and a mushroom tyrosinase inhibitor. Tyrosinase-IN-32 has antioxidant activity and can be isolated from black pepper (Piper nigrum L.) .
    Tyrosinase-IN-32
  • HY-160822
    AGG-523

    PF-5212371

    		 ADAMTS Inflammation/Immunology
    AGG-523 (PF-5212371) is a reversible, non-hydroxamate, zinc-binding selective aggrecanase 1 (ADAMTS4) and aggrecanase 2 (ADAMTS5) inhibitor. AGG-523 can be used for the study of osteoarthritis (OA) .
    AGG-523
  • HY-172734
    FG-2101

    		Bacterial Infection
    FG-2101 is a selective and orally active non-hydroxamate LpxC inhibitor with an IC50 of ~1 nM. FG-2101 exhibits exquisite selectivity over other bacterial and human metalloenzymes. FG-2101 can be used for the study of Gram-negative bacteria infections including drug-resistant strains .
    FG-2101
  • HY-175176
    HDAC1/6-IN-3

    		HDAC Apoptosis Pyroptosis Reactive Oxygen Species (ROS) Caspase Cancer
    HDAC1/6-IN-3 is a potent HDAC inhibitor. HDAC1/6-IN-3 shows excellent inhibitory activities against HDAC1 (IC50 = 1.1 nM) and HDAC6 (IC50 = 2.7 nM). HDAC1/6-IN-3 significantly arrests HepG2 cells at the G0/G1 phase and induces apoptosis and pyroptosis. HDAC1/6-IN-3 exhibits significant antitumor activity in the HepG2 xenograft mode. HDAC1/6-IN-3 can be used for the study of cancers such as liver cancer, lung cancer, colon cancer and breast cancer .
    HDAC1/6-IN-3
  • HY-10293
    Aderbasib

    INCB007839; INCB7839

    		 MMP Cancer
    Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 + breast cancer, gliomas, et al .
    Aderbasib
  • HY-131981
    TP0586532

    		Bacterial Infection Cardiovascular Disease
    TP0586532 is a non-hydroxamate LpxC inhibitor (IC50=0.101 μM). TP0586532 as a compound with a low cardiovascular risk that is effective against K. pneumoniae, including resistant strains . TP0586532 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    TP0586532
  • HY-131907
    LpxC-IN-5

    		Bacterial Infection
    LpxC-IN-5 is a potent non-hydroxamate LpxC (UDP-3-O-acyl-N-acetylglucosamine deacetylase) inhibitor with an IC50 of 20 nM. LpxC-IN-5 shows antibacterial activity against E. coli ATCC25922, P. aeruginosa ATCC27853, K. pneumoniae ATCC13883 and P. aeruginosa 5567 with MIC of 16, 4, 64, and 4 μg/mL, respectively .
    LpxC-IN-5
  • HY-129767
    CMLD012612

    		Eukaryotic Initiation Factor (eIF) Cancer
    CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity .
    CMLD012612
  • HY-W703549
    Aderbasib-d3

    INCB007839-d3; INCB7839-d3

    		 Isotope-Labeled Compounds MMP Cancer
    Aderbasib-d3 (INCB007839-d3) is deuterium labeled Aderbasib. Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 +?breast cancer, gliomas, et al .
    Aderbasib-d3
  • HY-161305
    SE-7552

    		HDAC Metabolic Disease Cancer
    SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM. SE-7552 is greater than 850-fold selectivity versus all other known HDAC isozymes. SE-7552 is capable of blocking multiple myeloma growth in vivo. SE-7552 acts as an anti-obesity agent in diet-induced obese mice .
    SE-7552
  • HY-P1997
    Ferrichrome Iron-free

    Desferrichrome; DFC; N-Desferriferrichrome

    		 Biochemical Assay Reagents Others
    Ferrichrome is a hydroxamate siderophore produced by various fungi, including U. sphaerogena, that facilitates iron chelation and uptake by these organisms. It can be used as a heterosiderophore by bacteria, including Pseudomonas aeruginosa and Vibrio parahaemolyticus. Ferrichrome (0.8 μM) inhibits concanavalin A-induced proliferation of mouse spleen monocytes and reduces the number of concanavalin A-stimulated CD4+ T cells expressing IL-2 receptor. It also inhibits the heme-catalyzed oxidation of LDL by hydrogen peroxide in a concentration-dependent manner.
    Ferrichrome Iron-free
  • HY-174803
    WMJ-J-09

    		p38 MAPK HDAC AMPK MDM-2/p53 Microtubule/Tubulin Pim Survivin Apoptosis Cancer
    WMJ-J-09 is an HDAC inhibitor with IC50 values of 7.5 nM (HDAC1), 21.3 nM (HDAC2), 18.4 nM (HDAC3), 90.9 nM (HDAC8), 3.9 nM (HDAC6) and 8715.7 nM (HDAC4). WMJ-J-09 blocks the cell cycle and induces apoptosis in cancer cells. WMJ-J-09 induces cancer cell death through the LKB1-AMPK-p38MAPK-p63-survivin signaling cascade.WMJ-J-09 inhibits HDAC enzyme activity, leading to acetylation of key proteins and thereby regulating cancer cell death. WMJ-J-09 can be used in HCT116 cells and FaDu cells research[1][2].
    WMJ-J-09

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: